Collagen-targeted PET Imaging for Early Interstitial Lung Disease

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT05417776
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Interstitial Lung Disease

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • [68Ga]CBP8 — DRUG
    An injection of up to 350 MBq of \[68Ga\]CBP8 will be administered intravenously followed by PET-MRI.
  • Dotarem — DRUG
    Dotarem will be administered during MRI portion of study.

Study Details

The goal of this study is to investigate the ability of \[68Ga\]CBP8 to detect collagen deposition in early interstitial lung disease.

Key Dates

Start date
Sep 28, 2022
Status verified
Apr 2026
Primary completion
Oct 1, 2026
Completion
Dec 1, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD)
    Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) will receive \[68Ga\]CBP8 and undergo PET-MRI.
  • Experimental: First degree relatives of a family member with pulmonary fibrosis
    First degree relatives of a family member with pulmonary fibrosis will receive \[68Ga\]CBP8 and undergo PET-MRI.

Primary Outcome Measure

Degree of uptake of [68Ga]CBP8 [ Time Frame: 24 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02114
Abimbola Akinniyi
Sydney Montesi, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital· Boston, MA

Related Studies